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Objectives The purpose of this pilot study was to evaluate the feasibility and safety of transcathe-
ter aortic valve implantation (TAVI) without balloon pre-dilation.
Background Balloon pre-dilation of the stenosed aortic valve is currently believed to be a necessary
step for valve preparation before device placement in patients undergoing TAVI and, therefore, is
considered an obligatory part of the procedure. However, clear evidence supporting this policy is
lacking. In contrast, pre-dilation might be responsible in part for distal embolizations as well as
atrioventricular conduction disturbances seen during TAVI procedures.
Methods A total of 60 consecutive patients (mean age 80.1  6.4 years, 53% female, mean logistic
EuroScore 23.3  15.2%) undergoing TAVI using the self-expanding Medtronic CoreValve prosthesis
(Medtronic, Minneapolis, Minnesota) have been prospectively enrolled at 13 international centers.
Results Pre-procedural mean transaortic valve gradient was 47.8  15.5 mm Hg, mean effective
oriﬁce area was 0.67  0.15 cm2. Technical success rate was 96.7% (58 of 60) of patients. Post-dila-
ion was performed in 16.7% (10 of 60) of patients. Post-procedural mean valve gradient was 4.4 
.0 mm Hg. Circular and noncircular valve conﬁguration was present in 41 and 19 cases (68.3% vs.
1.7%), respectively, with similar effective oriﬁce areas (1.74  0.10 cm2 vs. 1.71  0.22 cm2, p  NS). In-
hospital mortality, myocardial infarction, stroke, and major vascular complications occurred in 6.7%
(4 of 60), 0%, 5%, and 10% of patients. There was no valve embolization. New permanent pacing
was needed in 11.7% (7 of 60) of patients.
Conclusions Transcatheter aortic valve implantation without balloon pre-dilation is feasible and
safe, resulting in similar acute safety and efﬁcacy as the current standard approach of TAVI with
pre-dilation. (J Am Coll Cardiol Intv 2011;4:751–7) © 2011 by the American College of Cardiology
Foundation
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752Transcatheter aortic valve implantation (TAVI) has evolved
rapidly with an exponential growth of procedures performed
worldwide. Today, there is strong evidence that this tech-
nology is highly effective in patients with symptomatic
severe aortic valve stenosis and high surgical risk (1).
Compared with the very first experiences published in this
field (2–7), the technology has developed remarkably over
time, with new device generations, reduction of profile sizes,
and new access routes allowing for safer and more effica-
cious procedures in an expanding field of indications.
See page 758
Technical success rates up to 97% are now reported (8–14),
and the incidence of procedure-specific complications is
relatively low, given the high comorbid characteristics of the
currently treated patient population. However, the most
frequent complications are atrioventricular conduction dis-
turbances requiring permanent pacing, access site compli-
cations, paravalvular regurgitations, and cerebrovascular
events. Particularly, the incidence of strokes due to embo-
lization of fragments liberated from the fragile surface of a
degenerated stenosed valve, as
well as conduction disturbances
due to the close proximity of the
aortic annulus and the adjacent
left ventricular outflow tract to
the conduction system, are known
complications that have been re-
ported in surgical series and are
more or less linked to manipula-
tions within the degenerated native aortic valve at the
various steps of the procedure.
From the very beginning of the TAVI technology, valve
preparation by performing a balloon valvuloplasty before the
actual device placement has been considered a mandatory
step in a TAVI procedure to facilitate the implantation of
the prosthesis and reduce the radial counterforce to ensure
optimal device expansion. However, evidence supporting
this policy is lacking. Instead, balloon valvuloplasty, which
alone has been an established palliative procedure for
patients with aortic stenosis for more than 2 decades, carries
a specific complication risk (15–17) and can be responsible
by itself for distal embolizations resulting in strokes, con-
duction disturbances, and severe aortic regurgitation with
hemodynamic relevance. Therefore, we conducted a multi-
center pilot study to assess feasibility and safety of TAVI
without balloon pre-dilation.
Methods
Study design. We conducted a prospective pilot study
between 2009 and 2010, including 15 international heart
Abbreviations
and Acronyms
EuroScore  European
System for Cardiac Operative
Risk Evaluation
TAVI  transcatheter aortic
valve implantationcenters performing TAVI procedures using the self-expanding 18-F Medtronic CoreValve prosthesis (Medtronic,
Minneapolis, Minnesota). The objective was to demonstrate
the feasibility of TAVI without balloon pre-dilation, based
on technical success and hemodynamic results compared
with the current standard approach of TAVI with pre-
dilation. Because the study was designed as a pilot trial,
there was no prospective randomized control group. How-
ever, we retrospectively compared the results with the Safety
and Efficacy 18-F CoreValve study population, recently
published by our group (18).
Clinical and echocardiographic evaluation was performed
at baseline and after the procedure at hospital discharge
and/or 30-day follow-up. In addition, all patients under-
went pre-procedural computed tomography screening,
which was used to quantify valve calcification.
Patient inclusion criteria were defined as presence of
severe aortic stenosis (0.6 cm2/m2), aortic annulus diameter
ranging from 20 to 27 mm as determined by echocardiog-
raphy, ascending aorta diameter 45 mm 30 mm above the
annulus, age 75 years or surgical risk with logistic Euro-
Score (European System for Cardiac Operative Risk Eval-
uation) 15, or 1 to 2 high-risk comorbidities such as
cirrhosis of the liver, pulmonary insufficiency (forced expi-
ratory volume in 1 s 1 l), previous cardiac surgery,
pulmonary hypertension (systolic pulmonary pressure 60
mm Hg), porcelain aorta, right ventricular failure, or history
of mediastinal radiation therapy. All patients provided
written informed consent before the procedure.
Device and procedure. Design characteristics of the Core-
Valve prosthesis as well as the procedural characteristics
have been described elsewhere (7,8). Briefly, the current
18-F generation of the CoreValve prosthesis consists of a
trileaflet bioprosthetic porcine pericardial tissue valve, which
is mounted and sutured in a self-expanding nitinol stent
frame. The device is implanted retrogradely. The currently
commercially available third-generation device analyzed in
this study is offered in 2 different sizes (26 mm and 29 mm
prostheses) for different annulus dimensions ranging from
20 to 27 mm.
All patients underwent the standard TAVI screening
procedures including echocardiography and computed to-
mography as previously described, to assess dimensions and
morphologies of the aortic valve, the left ventricle, the aorta
as well as the peripheral access vessels. After gaining
vascular access and placement of a temporary pacemaker,
the left ventricle was entered with a hydrophilic wire, and 2
pigtail catheters were placed in the ventricle and in the
ascending aorta, followed by simultaneous pressure mea-
surements and gradient calculations. After placing a manu-
ally shaped, stiff guidewire in the ventricle and replacing the
pigtail catheter, the prosthesis was advanced over the aortic
arch and placed within the diseased native valve. Inability to
advance the prosthesis up to the final position within the
native valve was considered a device failure. The prosthesis
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753was then implanted within the native valve followed by
repeated invasive hemodynamic gradient assessments as well
as angiographic assessment of paravalvular regurgitation. In
case of significant paravalvular regurgitation (2), post-
dilation, implantation of a second device or conversion to
surgery was considered.
Deﬁnitions. In accordance with the recently published Valve
cademic Research Consortium definitions (19), technical
uccess was defined as successful vascular access, delivery,
nd deployment of the device with finally successful retrieval
f the delivery system; and correct position of the device in
he proper anatomical location with adequate performance
f the prosthetic heart valve (mean pressure gradient 20
m Hg) and without use of multiple prostheses. Myocar-
ial infarction was defined as elevation of creatine kinase
wice the upper limit of normal with the presence of
levated creatine kinase-myocardial band above the upper
imit of normal with electrocardiographic evidence of isch-
mia and a compatible clinical history. Stroke was defined as
new, prolonged (24 h) or permanent neurological deficit.
Statistical analysis. Categorical variables are presented as
requencies and percentages. Continuous variables are pre-
ented as mean  SD.
esults
A total of 60 consecutive patients (mean age: 80.1  6.4
years, 53% female, mean logistic EuroScore: 23.3  15.2%)
undergoing TAVI using the self-expanding 18-F
Medtronic CoreValve prosthesis have been enrolled in this
pilot study. Indication for TAVI was a symptomatic aortic
valve stenosis in all patients (transvalvular gradient from 47.8
15.5 mm Hg). The historic control group consisted of 126
patients (mean age: 81.9  6.4 years, 57% female, mean
logistic EuroScore: 23.4  13.8%) who underwent the same
procedure using the 18-F CoreValve device (Table 1).
Technical success rate was 96.7% (58 of 60) of patients in
the study population compared with 81.7% in the control
group. In 2 patients, the prosthesis was implanted too high,
with subsequent implantation of a second device after
retraction of the first one into the ascending and descending
aorta, respectively. This resulted in a good hemodynamic
result in 1 patient; the other patient had to be converted to
surgery with explantation of both devices but died shortly
thereafter. Post-dilation was performed in 16.7% (10 of 60)
of patients in the study population. An example of a
successfully implanted prosthesis without pre-dilation is
shown in Figure 1. There was no valve embolization in either
group. New permanent pacing was needed in 11.7% (7 of
60) of patients in the pilot study population compared with
27.8% in the control (Tables 2 and 3).
Echocardiographic outcome. Comparing baseline and post-
procedural echocardiographic follow-up data, there was a
significant reduction of the mean transvalvular gradientfrom 47.8 15.5 mm Hg to 4.4 2.0 mm Hg in the study
population and from 46.8  15.9 mm Hg to 8.5  4.0 mm
Hg in the control population (p  0.001) (Fig. 2). Similar
comparable improvements were observable with regard to
the effective orifice area, increasing from 0.66  0.2 cm2 to
1.72 0.2 cm2 and from 0.72 0.2 cm2 to 1.80 0.4 cm2
in the study and in the control group. Circular and noncir-
cular valve configuration was present in 41 and 19 cases
(68.3% vs. 31.7%) with similar effective orifice areas (1.74
.10 cm2 vs. 1.71  0.22 cm2, p  NS). Aortic regurgita-
ion of any kind was present in 82% and 58% of study and
ontrol patients at baseline, respectively, compared with
8% and 41% after the procedure. There was severe aortic
egurgitation (3) at baseline in 2% of patients of the study
opulation, but there was no severe regurgitation in any
roup after the procedure (Fig. 3). Initial degree of calcifi-
ation of the aortic valve has been judged by echocardiog-
aphy and/or computed tomography to be severe in 25 cases
41.7%), moderate in 35 cases (58.3%), and mild in 2 cases
3.3%).
Major adverse cardiac and cerebrovascular events. Follow-up
availability was 100% in the pilot study population and
99.2% (125 of 126) of patients at 30 days in the control
group. All-cause mortality up to 30 days was 6.7% versus
14.3% in the pilot study and the control group, respectively.
A total of 4 patients died in the study group: 1 patient after
Table 1. Baseline Clinical Patient Characteristics
Study Group
(n  60)
Control Group
(n  126)
Age, yrs 80.1 6.4 81.9 6.4
Male 46.7% (28) 42.9% (54)
EuroScore 23.3 15.2 23.4 13.8
Hypertension 41.7% (25) 79.4% (100)
Diabetes mellitus 18.3% (11) 26.2% (33)
Smoker 40.0% (24) 32.5% (41)
Coronary heart disease 61.7% (37) 65.9% (83)
Previous myocardial infarction 6.7% (4) 19.0% (24)
Previous CABG 23.3% (14) 26.2% (33)
Previous coronary angioplasty 26.7% (16) 23.8% (30)
Peripheral vascular disease 18.3% (11) 19.0% (24)
Previous stroke or TIA 3.3% (2) 22.2% (28)
Pulmonary hypertension 21.7% (13) 31.7% (40)
Renal insufﬁciency 26.7% (16) 43.7% (55)
Chronic lung disease 18.3% (11) 23.0% (29)
Previous pacemaker 10.0% (6) 7.9% (10)
NYHA functional class 1 0 5.6% (7)
NYHA functional class 2 13.3% (8) 19.8% (25)
NYHA functional class 3 70.0% (42) 54.0% (68)
NYHA functional class 4 16.7% (10) 20.6% (26)
Values are mean SD or % (n).
CABG coronary artery bypass grafting; EuroScore European System for Cardiac Operative
Risk Evaluation; NYHA New York Heart Association; TIA transient ischemic attack.unsuccessful placement of 2 devices and subsequent need for
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754conversion to surgery (day 1), 1 patient due to worsening
right heart failure on day 3, and 2 patients due to pneumo-
nia and septicemia on day 10 and 13, respectively. Myocar-
dial infarction, stroke, and vascular complications occurred
in 0%, 5%, and 10% of patients in the study group as
compared with 5.6%, 11.9%, and 9.5% of patients in the
control group.
Discussion
This pilot study provides the first evidence that balloon
valvuloplasty for pre-dilation of the stenosed aortic valve in
patients undergoing TAVI could be omitted due to lack of
relevant beneficial procedural effects.
Since the first transcatheter aortic heart valve implan-
tation, balloon valvuloplasty has been considered a man-
datory step of the procedure for theoretical reasons to
“prepare the grounds,” given the nature of both the
degenerated valve as well the TAVI procedure. Degen-
erative aortic valve stenosis, the leading cause of aortic
Figure 1. Computed Tomography After CoreValve Implantation Without
Pre- and Post-Dilation in a Patient With Significant Aortic Valve Stenosis
Demonstration of symmetrical circular and complete expansion of the
inﬂow portion of the prosthesis.
Table 2. Procedural Results
Study Group
(n  60)
Control Group
(n  126)
Technical success rate 96.7% (58) 81.7% (103)
Valve embolization 0 0
Conversion to surgery 1.7% (1) 5.6% (7)
Post-dilation 16.7% (10) NA
Values are % (n).NA not available.stenosis in the elderly, is considered a form of athero-
sclerosis with mild to heavy calcifications such as active
bone formation on the aortic leaflet side of up to all 3
cusps. In addition, this process, as well as inflammation,
rarely causes fusion of the commissures resulting in
functionally bi- or even monocuspid valves. The tech-
nique of aortic balloon valvuloplasty, adopted from val-
vuloplasties for treatment of pulmonary stenosis, re-
coarctation, and mitral stenosis, has been a palliative
method for more than 2 decades with promising initial
(20) and short-term results, but analysis of larger popu-
lations has demonstrated poor long-term outcome with
high recurrence rates (21). The acute effects of balloon
valvuloplasty on the aortic valve apparatus are only poorly
understood, but include fracturing calcified nodules, sep-
arating fused commissures, and stretching of the aortic
valve ring, all resulting in acute gain of the effective aortic
orifice area. Because only microfractures are usually
achieved, the rate of restenosis remains high within the
first months after intervention, and the procedure is
limited by a considerable periprocedural mortality and
morbidity with risk of strokes, severe conduction distur-
bances, severe aortic regurgitation, and decompensation.
The acute theoretical effects on the valve apparatus, includ-
ing the acute orifice gain, were the justification and rationale
to implement pre-dilation in the TAVI procedure as a
preparatory step just before implantation of the prosthesis,
to facilitate the introduction of the device within the
diseased aortic valve and to enable an optimized expansion
by possibly reducing radial counterforces.
Our pilot study, performing TAVI without balloon
pre-dilation, demonstrates the feasibility of this new ap-
proach, which might have the potential to facilitate the
procedural steps of TAVI. Without pre-dilation, the tech-
nical success rate in our study population, defined as
successful placement of the device within the stenosed
native valve and successful implantation without significant
remaining gradient, is higher than the success rate in the
chosen control population, which still reflects the early
experience with this technology, and is as high as in more
recently enrolled patient populations in experienced sites,
Table 3. Clinical Short-Term Outcome
Study Group
(n  60)
Control Group
(n  126)
All-cause mortality 6.7% (4) 14.3% (18)
Myocardial infarction 0 5.6% (7)
Stroke/TIA 5.0% (3) 11.9% (15)
Need for pacemaker implantation 11.7% (7) 27.8% (35)
Vascular access complication 10.0% (6) 9.5% (12)
Values are % (n).
TIA transient ischemic attack.which report rates of 90% to 97% (8–14). Partially respon-
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755sible for this high technical success rate observed in our
study, demonstrating the ease of placing the prosthesis
within the native valve, is certainly the relatively low device
profile of 18-F, which facilitates the insertion of the device
in the stenosed valve.
Equally important, we could demonstrate that acute
hemodynamic effects are almost identical in patients under-
Figure 2. Transthoracic Echocardiographic Data Pre- and Post-Dilation
Peak pressure gradients by transthoracic echocardiography pre- and post-
dilation (A), mean pressure gradients pre- and post-dilation (B), and effec-
tive oriﬁce area pre- and post-dilation (C), demonstrating equivalent
changes in both the study and control populations.going TAVI without and with pre-dilation (Fig. 2). Thereis no risk of higher residual gradients in patients without
pre-dilation, which could have been a concern due to the
lack of “preparing” the native valve. The same holds true for
the risk of paravalvular regurgitation after device placement,
which is not accentuated in the pilot study population
compared with the control. Noncircular valve expansion was
detectable in 32% of patients, but this did not affect the
orifice area or hemodynamics. Because little is known so far
on geometry of TAVI prostheses in general, further studies
are certainly needed to gather more information on this
topic, particularly with regard to incidence and long-term
effects of relevant noncircular expansion.
The radial force provided by the TAVI device itself—the
CoreValve prosthesis in this case—is obviously sufficient to
guarantee a good expansion in most cases. In case of
underexpansion, post-dilation can be easily performed, but
the need for post-dilation, around 17% in our series, is
comparable to other reports (8) and does not indicate a
higher rate associated with this new strategy.
Given the low number of enrolled patients, it is difficult
to draw meaningful conclusions from the clinical event
rates, but the results with regard to mortality, strokes, and
myocardial infarction compare favorably with the control
group as well as with recently published trials (11–14). The
need for permanent pacing in only 12% of patients is
particularly promising compared with other studies using
the CoreValve device (9,11,18). Finally, temporary, high-
frequency ventricular pacing, which is usually performed
during balloon valvuloplasty to create a functional stand-still
of the heart, is not needed during a TAVI procedure
without pre-dilation using the CoreValve technology,
which implies at least some theoretical benefits, particularly
in patients with heart failure and/or severe reduced ejection
fraction.
Given the results of this pilot study, TAVI without
balloon pre-dilation seems to be feasible and should be
investigated further in larger trials, including randomized
studies, as this strategy presents an additional attractive
facilitation of the procedure, with potential safety benefits.
Study limitations. The study enrolled only a limited number
of patients. In addition, the historic control group reported
in this paper is not equivalent to a randomized or matched
control, which needs to be considered when comparing the
results of both study populations. Since the control group
reflects the early experience with the 18-F CoreValve
prosthesis, the results might be affected by learning curve
issues. Therefore, larger and randomized trials are needed to
provide more insights into this new approach and its value
compared with the established techniques. Whether the
findings reported in this paper are applicable to a balloon-
expandable TAVI technology is unknown so far and must
be evaluated in a specific trial.
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756Conclusions
TAVI without balloon pre-dilation is feasible and safe,
resulting in similar acute safety and efficacy as the current
standard approach of TAVI with pre-dilation.
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APPENDIX
For a list of participating centers in order of enrolled patients, please see
the online version of this article.
